Kevin Kish

3.0k total citations · 1 hit paper
38 papers, 2.0k citations indexed

About

Kevin Kish is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, Kevin Kish has authored 38 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 11 papers in Organic Chemistry and 7 papers in Computational Theory and Mathematics. Recurrent topics in Kevin Kish's work include Melanoma and MAPK Pathways (8 papers), Computational Drug Discovery Methods (6 papers) and Biochemical and Molecular Research (5 papers). Kevin Kish is often cited by papers focused on Melanoma and MAPK Pathways (8 papers), Computational Drug Discovery Methods (6 papers) and Biochemical and Molecular Research (5 papers). Kevin Kish collaborates with scholars based in United States, Germany and Japan. Kevin Kish's co-authors include Susan E. Kiefer, Herbert E. Klei, Dianlin Xie, John S. Sack, Yaqun Zhang, John A. Newitt, John S. Tokarski, Michael Wittekind, Louis J. Lombardo and Janet Cheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

Kevin Kish

38 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants

2006 522 citations John S. Tokarski, John A. Newitt et al. profile →

Peers

Countries citing papers authored by Kevin Kish

Since Specialization

Citations

This map shows the geographic impact of Kevin Kish's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Kish with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Kish more than expected).

Fields of papers citing papers by Kevin Kish

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Kish. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Kish. The network helps show where Kevin Kish may publish in the future.

Co-authorship network of co-authors of Kevin Kish

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Kish. A scholar is included among the top collaborators of Kevin Kish based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Kish. Kevin Kish is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure–activity relationship (SAR) studies on substituted N-(pyridin-3-yl)-2-amino-isonicotinamides as highly potent and selective glycogen synthase kinase-3 (GSK-3) inhibitors 2023 ·Bioorganic & Medicinal Chemistry Letters ·Guanglin Luo, Ling Chen, (unknown), Ying Han, Catherine R. Burton, Hong Xiao, Carol Krause, Yang Cao, (unknown), Kevin Kish, H.A. Lewis, John E. Macor, Gene M. Dubowchik	9
2	Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs 2022 ·Journal of Medicinal Chemistry ·B. Narasimhulu Naidu, Manoj Patel, Brian McAuliffe, Bo Ding, Christopher Cianci, (unknown), Susan Jenkins, Dawn D. Parker, Prasanna Sivaprakasam, Javed Khan, Kevin Kish, H.A. Lewis, Umesh Hanumegowda, Mark Krystal, Nicholas A. Meanwell, John F. Kadow	8
3	Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage 2019 ·ACS Medicinal Chemistry Letters ·Amy C. Hart, Lynn M. Abell, Junqing Guo, Michael Mertzman, Ramesh Padmanabha, John E. Macor, Charu Chaudhry, Hao Lu, K O'Malley, Patrick J. Shaw, Carolyn A. Weigelt, Matthew Pokross, Kevin Kish, Kyoung S. Kim, Lyndon A. M. Cornelius, (unknown), (unknown), Ping Zhang, Brian Carpenter, William J. Pitts	31
4	Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core 2015 ·Bioorganic & Medicinal Chemistry Letters ·Prasanna Sivaprakasam, Xiaojun Han, Rita L. Civiello, (unknown), Kevin Kish, (unknown), H.A. Lewis, (unknown), (unknown), John A. Newitt, Eric T. Baldwin, Hong Xiao, Carol Krause, Hyunsoo Park, (unknown), Jonathan Lippy, Catherine R. Burton, David R. Langley, John E. Macor, Gene M. Dubowchik	100
5	The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode 2013 ·Bioorganic & Medicinal Chemistry Letters ·Stephen T. Wrobleski, Shuqun Lin, T. G. Murali Dhar, Alaric J. Dyckman, Tianle Li, Sidney Pitt, Rosemary Zhang, Yi Fan, Arthur M. Doweyko, John S. Tokarski, Kevin Kish, Susan E. Kiefer, John S. Sack, John A. Newitt, Mark R. Witmer, Murray McKinnon, Joel C. Barrish, John H. Dodd, Gary L. Schieven, Katerina Leftheris	15
6	Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·Alaric J. Dyckman, Tianle Li, Sidney Pitt, Rosemary Zhang, Ding Ren Shen, Kim W. McIntyre, Kathleen M. Gillooly, David J. Shuster, Arthur M. Doweyko, John S. Sack, Kevin Kish, Susan E. Kiefer, John A. Newitt, Hongjian Zhang, Punit H. Marathe, Murray McKinnon, Joel C. Barrish, John H. Dodd, Gary L. Schieven, Katerina Leftheris	9
7	7-Oxopyrrolopyridine-derived DPP4 inhibitors—mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site 2011 ·Bioorganic & Medicinal Chemistry Letters ·Wei Wang, Pratik Devasthale, Aiying Wang, (unknown), (unknown), Nathan Morgan, Michael Cap, Aberra Fura, Herbert E. Klei, Kevin Kish, Carolyn A. Weigelt, Lucy Sun, Paul Lévesque, Yixin Li, Robert Zahler, Mark Kirby, Lawrence G. Hamann	15
8	Cloning, purification, crystallization and preliminary X-ray analysis of the catalytic domain of human receptor-like protein tyrosine phosphatase γ in three different crystal forms 2011 ·Acta Crystallographica Section F Structural Biology and Crystallization Communications ·Kevin Kish, Patricia A. McDonnell, Valentina Goldfarb, Mian Gao, William J. Metzler, David R. Langley, James W. Bryson, Susan E. Kiefer, Brian Carpenter, Walter A. Kostich, Ryan S. Westphal, S. Sheriff	2
9	Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase 2011 ·Bioorganic & Medicinal Chemistry Letters ·Robert G. Gentles, S. Sheriff, Brett R. Beno, (unknown), Kevin Kish, Min Ding, Xiaofan Zheng, Louis Chupak, Michael A. Poss, Mark R. Witmer, Paul E. Morin, Ying-Kai Wang, Karen Rigat, Julie A. Lemm, Stacey Voss, Mengping Liu, (unknown), Susan B. Roberts, Min Gao, John F. Kadow	8
10	Phenyltriazolinones as potent factor Xa inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Mimi L. Quan, Donald Pinto, Karen A. Rossi, S. Sheriff, Richard Alexander, (unknown), Kevin Kish, Robert M. Knabb, Joseph M. Luettgen, Paul E. Morin, Angela Smallwood, Francis J. Woerner, Ruth R. Wexler	10
11	Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Yan Shi, Jing Zhang, Mengxiao Shi, Stephen P. O’Connor, (unknown), Chi Li, Doree Sitkoff, Andrew T. Pudzianowski, Saeho Chong, Herbert E. Klei, Kevin Kish, Joseph Yanchunas, Eddie C.‐K. Liu, Karen S. Hartl, (unknown), Thomas E. Steinbacher, William A. Schumacher, Karnail S. Atwal, Philip D. Stein	13
12	Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation 2008 ·Protein Science ·William J. Metzler, Joseph Yanchunas, Carolyn A. Weigelt, Kevin Kish, Herbert E. Klei, Dianlin Xie, Yaqun Zhang, Martin J. Corbett, James Tamura, Bin He, Lawrence G. Hamann, Mark Kirby, Jovita Marcinkeviciene	103
13	Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38α MAP kinase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Stephen T. Wrobleski, Shuqun Lin, John Hynes, Hong Wu, Sidney Pitt, Ding Ren Shen, Rosemary Zhang, Kathleen M. Gillooly, David J. Shuster, Kim W. McIntyre, Arthur M. Doweyko, Kevin Kish, Jeffrey Tredup, Gerald J. Duke, John S. Sack, Murray McKinnon, John H. Dodd, Joel C. Barrish, Gary L. Schieven, Katerina Leftheris	25
14	Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase 2008 ·Acta Crystallographica Section D Biological Crystallography ·John S. Sack, Kevin Kish, Matthew Pokross, Dianlin Xie, Gerald J. Duke, Jeffrey Tredup, Susan E. Kiefer, John A. Newitt	10
15	Benzothiazole based inhibitors of p38α MAP kinase 2008 ·Bioorganic & Medicinal Chemistry Letters ·Chunjian Liu, James C. Lin, Sidney Pitt, (unknown), John S. Sack, Susan E. Kiefer, Kevin Kish, Arthur M. Doweyko, Hongjian Zhang, Punit H. Marathe, James M. Trzăskos, Murray McKinnon, John H. Dodd, Joel C. Barrish, Gary L. Schieven, Katerina Leftheris	47
16	Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38α inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Jagabandhu Das, Robert V. Moquin, Sidney Pitt, Rosemary Zhang, Ding Ren Shen, Kim W. McIntyre, Kathleen M. Gillooly, Arthur M. Doweyko, John S. Sack, Hongjian Zhang, Susan E. Kiefer, Kevin Kish, Murray McKinnon, Joel C. Barrish, John H. Dodd, Gary L. Schieven, Katerina Leftheris	37
17	Pharmacological and X-Ray Structural Characterization of a Novel Selective Androgen Receptor Modulator: Potent Hyperanabolic Stimulation of Skeletal Muscle with Hypostimulation of Prostate in Rats 2006 ·Endocrinology ·Jacek Ostrowski, (unknown), John A. Lupisella, (unknown), Blake C. Beehler, Stanley R. Krystek, Yingzhi Bi, Chong‐Qing Sun, Ramakrishna Seethala, Rajasree Golla, Paul G. Sleph, Aberra Fura, Yongmi An, Kevin Kish, John S. Sack, Kasim A. Mookhtiar, Gary J. Grover, Lawrence G. Hamann	99
18	Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP) 2006 ·Bioorganic & Medicinal Chemistry Letters ·Richard Sulsky, David R. Magnin, Yanting Huang, Ligaya M. Simpkins, Prakash C. Taunk, Manorama M. Patel, Yeheng Zhu, Terry R. Stouch, Donna Bassolino‐Klimas, Rex A. Parker, Thomas Harrity, Robert H. Stoffel, David S. Taylor, Thomas Lavoie, Kevin Kish, Bruce L. Jacobson, S. Sheriff, Leonard P. Adam, William R. Ewing, Jeffrey A. Robl	126
19	Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists 2004 ·Bioorganic & Medicinal Chemistry Letters ·Mark Salvati, Aaron Balog, Weifang Shan, Donna Wei, (unknown), Ricardo M. Attar, Jieping Geng, Cheryl A. Rizzo, Marco M. Gottardis, Roberto Weinmann, Stanley R. Krystek, John S. Sack, Yongmi An, Kevin Kish	48
20	The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor. 2004 ·Blood ·John S. Tokarski, John A. Newitt, Francis Y. Lee, Louis J. Lombardo, R. M. Borzilleri, Kevin Kish, Dianlin Xie, Yaqun Zhang, Janet Cheng, Susan E. Kiefer, (unknown), Herbert E. Klei	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact